Creating Cures and Values to Patients
We're dedicated to innovation!
Creating Cures and Values to Patients
We're dedicated to innovation!
ABOUT US
About Longwood Pharmaceuticals
Longwood Pharmaceuticals is an innovative, research-based startup biopharmaceutical company based in China and the U.S, established by a world-class team of veteran scientists in drug discovery. We are committed to developing and commercializing first-in-class and best-in-class medicine to treat vascular diseases in China and worldwide.
The company is headquartered in Beijing and has starting capital of $30 million. We are rapidly expanding into a fully integrated biopharmaceutical company. We have built our internal R&D center to advance our discovery pipeline, robust clinical development, and business operation team and are considering setting up our manufacturing facilities in China. We have also established a highly specialized commercial team to support the marketing of our innovative products in China.
OUR FOCUS
Focus on
- Diabetic macular edema（DME）
- Wet age-related macular degeneration （wet AMD）
- Macular edema following retinal retinal vein occlusion （ME-RVO）
The drug targets
- Plasma kallikrein（PK）
- Cytokines
- Intergrin
- Rho/Rho Kinase（ROCK）
- Complement（H,C3,C5）
SENIOR MANAGEMENT
George Wu
Yiqin Zhang
Yiqin Zhang
Dr. Wu is founder and Chief Executive Officer of Longwood Pharmaceuticals. Previously he was an academic research veteran at Harvard Medical School with more than 10 years experience of molecular pathway and drug target finding in neuroscience and vascular biology. He founded and served as CEO of Mass Medical International Corp (MMI) with
Dr. Wu is founder and Chief Executive Officer of Longwood Pharmaceuticals. Previously he was an academic research veteran at Harvard Medical School with more than 10 years experience of molecular pathway and drug target finding in neuroscience and vascular biology. He founded and served as CEO of Mass Medical International Corp (MMI) with a proven track record of successful team building, management, and business development. During his tenure as the CEO of MMI, the company grew from startup to a global organization of more than 300 employees. He is also a partner of Fosun Capital Group, an international financial service company in the healthcare industry
__________
He received his M.D. from Guangzhou Medical University, China; his Ph.D. from Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences & Harvard Medical School
Yiqin Zhang
Yiqin Zhang
Yiqin Zhang
Dr. Zhang is a neural-ophthalmologist and physician-scientist with over 25 years of clinical and drug development experience. She was co-owner and President of Myadvice Consultant Group, where she provided supervision for clinical development strategy, clinical trial design, and regulatory submission. Dr. Zhang worked for Novartis, where
Dr. Zhang is a neural-ophthalmologist and physician-scientist with over 25 years of clinical and drug development experience. She was co-owner and President of Myadvice Consultant Group, where she provided supervision for clinical development strategy, clinical trial design, and regulatory submission. Dr. Zhang worked for Novartis, where she served as the small molecule pipeline team leader for delivering oral and topical VEGF and complement C3 inhibitors to the clinic through line function. Before her pharmaceutical industry experience, Dr. Zhang was a senior ophthalmologist and physician-in-charge in Zhongshan Eye Hospital, Guangzhou, China. She is an inventor or author on more than 20 patents and publications in the field of Ophthalmology
__________
Dr. Zhang received her M.D. from Jiangxi Medical School, Jiangxi, China, her Ph.D. in Neural-Ophthalmology from Lund University, Lund, Sweden, and her Post-Doctoral Fellowship from Harvard Medical School. She also received her M.S. in Neurology from Sun Yat-sen University Zhongshan Medical School
Xiaoming Wu
Xiaoming Wu
Xiaoming Wu
Dr. Xiaoming Wu has worked for Anikon Drug Research and Development, New Jersey, U.S.A., Zhejiang Kyushu Pharmaceutical, and Wuhan Kerry Kangning Bio Co. He has over 20 years of practical experience in synthetic chemistry of small molecules, carbohydrates and peptides; experienced in process development/optimization, analytical developmen
Dr. Xiaoming Wu has worked for Anikon Drug Research and Development, New Jersey, U.S.A., Zhejiang Kyushu Pharmaceutical, and Wuhan Kerry Kangning Bio Co. He has over 20 years of practical experience in synthetic chemistry of small molecules, carbohydrates and peptides; experienced in process development/optimization, analytical development and validation of small molecule APIs and intermediates, from laboratory studies to pilot plant scale-up and commercial production
__________
Dr. Wu received his Ph.D. in Organic Chemistry Synthesis from Wayne State University, Michigan, USA and his M.S. in Organic Chemistry Synthesis from Hong Kong University of Science and Technology, Hong Kong
Wenqi Jiang
Xiaoming Wu
Xiaoming Wu
Dr. Jiang has served as Deputy Director of the Center for Cancer Prevention and Treatment of Zhongshan University, Vice President of the Cancer Hospital of Zhongshan University and Director of the Department of Internal Medicine, Vice Director of the Institute of Clinical Pharmacology of Zhongshan University and Director of the Academic C
Dr. Jiang has served as Deputy Director of the Center for Cancer Prevention and Treatment of Zhongshan University, Vice President of the Cancer Hospital of Zhongshan University and Director of the Department of Internal Medicine, Vice Director of the Institute of Clinical Pharmacology of Zhongshan University and Director of the Academic Committee of the National Center for Clinical Trials of New Antitumor Drugs
__________
Dr. Jiang graduated from Shanghai Medical University in clinical oncology and was Associate Professor at M.D. Anderson Cancer Center and other institutions in the United States
OUR CULTURE
Integrity and Innovation
Responsibility and Efficiency
JOIN US
- CRA
- PM
- BD Consultant